Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Abrocitinib may effectively treat stubborn alopecia universalis.

Upadacitinib helped regrow hair and maintain ulcerative colitis remission.

Tofacitinib works well for treating alopecia areata, especially when combined with corticosteroids, but is less effective if the disease has lasted over 2 years.

Tofacitinib was more effective than apremilast in treating hair loss in a mouse model of alopecia areata.

Alefacept showed some effectiveness for alopecia areata but needs more research.

Upadacitinib significantly improved alopecia universalis and psoriatic arthritis in a patient.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Abrocitinib helped a 14-year-old girl with severe alopecia areata regrow her hair significantly.

Upadacitinib may help treat difficult cases of systemic lupus erythematosus.

Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.

Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.

Apremilast did not work for treating severe alopecia areata.

Tofacitinib was more effective than methotrexate for treating alopecia areata.

A new drug, abrocitinib, helped a child with severe hair loss regrow hair.

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

A woman with severe hair loss was successfully treated with the drug adalimumab.

Brodalumab is more effective than ustekinumab for treating psoriasis.

Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.

Abrocitinib effectively treated severe atopic dermatitis and mild alopecia areata in a 12-year-old boy after dupilumab failed.

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.

Etanercept may not prevent alopecia areata from coming back.